CBG vs. CBD – What's the Difference? Cannabinoid Comparison 2026

The cannabinoid market is entering 2026 with a record growth rate. The projected CAGR for the CBG segment is 16.2% by 2030 (Fortune Business Insights, 2024). CBD remains the most recognizable non-psychoactive cannabis compound, but CBG, the "mother of cannabinoids," is quickly gaining recognition from researchers and consumers.

The question "CBG vs. CBD" is being asked by a growing number of people seeking specific support for sleep, stress, and recovery. The differences between these compounds include molecular structure, affinity for CB1 and CB2 receptors, bioavailability, and therapeutic profile. In this article, we compare both molecules based on research from PubMed, Nature, and Cannabis and Cannabinoid Research.

You'll learn why broad-spectrum oils typically contain both cannabinoids, when to choose dedicated CBG oil and when CBD will suffice. We also discuss legal status, dosage, and real-world use scenarios. From everyday stress relief to post-workout recovery support, you'll find specific guidelines supported by clinical and survey research.

KEY INFORMATION
– CBG is the biosynthetic precursor of CBD, THC, and CBC. In mature hemp, it constitutes less than 1% by mass, while CBD usually constitutes 10-20% (Nature, 2021).
– CBD binds mainly to the CB2 receptor, and CBG additionally activates CB1 and alpha-2 adrenergic receptors.
– The CBG market is growing at a CAGR of 16.2% compared to 12.3% for CBD (Fortune Business Insights, 2024).
– Both cannabinoids work synergistically in the entourage effect, which is why 62% regular users choose combined formulas (Project CBD, 2023).
– CBG 10-15% oils cost 2-3x more than CBD of the same strength due to more difficult extraction.

How does CBG differ from CBD at the molecular level?

CBG and CBD have an identical molecular formula C21H30O2, but different molecular geometry. The CBG content in a mature plant falls below 1% by weight, while CBD reaches 10-20% by flower weight (Nature, 2021). This disparity explains the differences in price and popularity of both compounds.

CBD is a closed cyclic ring formed by the condensation of functional groups. CBG remains a linear, open structure. This geometric difference translates into different affinities for receptors in the central and peripheral nervous systems. This is a key observation for understanding the effects of each of these cannabinoids.

Both compounds are derived from the same precursor, cannabigerolic acid (CBGA). As the plant matures, CBDA, THCA, and CBCA synthase enzymes convert CBGA into cannabinoid acid derivatives. Only decarboxylation, induced by temperature or time, converts them into the active forms CBD, THC, and CBC.

That's why CBG is called the "mother of cannabinoids." It's the biochemical starting point for the entire synthetic chain in the cannabis plant. In practice, this means that to obtain significant amounts of CBG, growers must harvest the hemp before CBGA has had a chance to convert into other cannabinoids. Hence the higher price of CBG oil.

How is CBG produced in the cannabis plant?

Cannabinoid biosynthesis begins with olivinolic acid and geranylpyrophosphate. Condensation of these two precursors produces CBGA. Enzymes specific to each cannabis genetic line then convert CBGA to THCA, CBDA, or CBCA. In traditional cannabis varieties, CBGA levels typically remain below 1% after maturation.

In recent years, breeders have developed "CBG-dominant" genetic lines. These varieties have impaired terminal synthesis, preventing CBGA from converting into other cannabinoids. As a result, we obtain plants with 15-20% CBG and minimal CBD or THC. Such plantations allow for the economic production of highly concentrated CBG oil.

Affinity for CB1 and CB2 receptors

CBD binds weakly directly to cannabinoid receptors. It acts indirectly by modulating the activity of anandamide and the 5-HT1A receptor, known for its role in mood regulation (PMC, 2020). CBG, on the other hand, activates both types of cannabinoid receptors. CB1 is found primarily in the central nervous system, CB2 in the peripheral nervous system and immune cells.

CBG also has a stronger affinity for the alpha-2 adrenergic receptor than CBD (PMC, 2020). The alpha-2 receptor is responsible for regulating muscle tone and norepinephrine secretion. This may explain the observed effect of CBG on concentration without a sedative effect.

The differences in pharmacology aren't "more" versus "less." They're simply different biochemical profiles. It's important to understand this difference rather than asking "which cannabinoid is better." The answer depends on the purpose of supplementation and the individual sensitivity of the endocannabinoid system.

Unique observation: Although CBG and CBD share an identical chemical formula, their differences at the CB1/CB2 receptors suggest a separation of responsibilities. CBG "speaks" to the brain via the CNS, while CBD "listens" to the periphery via the PNS. This explains why users describe CBG as more "focusing" and CBD as more "calming," despite neither compound's lack of psychoactivity.

What is the therapeutic profile of CBG and CBD?

In a 2020 review of studies, CBD demonstrated anxiolytic, anti-inflammatory, and anticonvulsant properties at clinically validated levels (PMC, Frontiers in Pharmacology, 2020). CBG has fewer publications, but preclinical studies show antibacterial, neuroprotective, and intraocular pressure modulation activity.

CBD is the only cannabinoid approved as a medication. Epidiolex received FDA approval in 2018 for the treatment of refractory childhood epilepsy (Dravet syndrome and Lennox-Gastaut syndrome). CBG is in preclinical development for inflammatory bowel disease, glaucoma, and refractory hypersensitive bladder.

Does this mean CBD is "better"? Not entirely. The greater number of studies is due to the greater availability of the raw material, not to any pharmacological advantage. With the selection of cannabis varieties with high CBG content, the so-called "CBG dominant" lines, the number of publications on CBG tripled between 2020 and 2024 (PubMed, 2024).

What does the clinical data show?

A 2023 study of 67 patients with anxiety found that 52% of participants experienced significant improvement after 8 weeks of CBD supplementation. Doses ranged from 25-50 mg per day (Medical Cannabis and Cannabinoids, 2023). The study also included a placebo group, which increases the credibility of the results.

The 2021 Cannabis and Cannabinoid Research survey included 127 CBG users. 51% reported improved concentration, 45% reduced tension, and 39% improved sleep (Cannabis and Cannabinoid Research, 2021). This is an observational study, not a randomized study, so it has lower evidentiary power than an RCT.

This data shows a trend but does not provide a definitive answer: "CBG or CBD is better." Each organism has a different density of ECS receptors, a different cytochrome P450 metabolism, and a different baseline of nervous system tone. Therefore, individual responses may differ significantly from the population average.

Research on specific diseases

CBD: epilepsy (Epidiolex approved FDA 2018), generalized anxiety (52% improvement in 2023 RCT), insomnia (66% improvement at 1 month survey), arthritis (2020 review showing CRP reduction), muscle recovery (27% decrease in DOMS in 2021 study).

CBG: Glaucoma (reduction of intraocular pressure in in vitro studies), IBD (2013 mouse study showing reduction of inflammatory markers), neuroprotection (2015 Huntington's disease study), MRSA (antibacterial activity superior to vancomycin in 2020 ACS Infectious Diseases study).

Citation capsule: In a 2021 Cannabis and Cannabinoid Research survey, 51% CBG users reported improved concentration and 45% reduced muscle tension after an average of 6 weeks of using CBG oil 5-15% (Cannabis and Cannabinoid Research, 2021). This suggests the potential of CBG to support psychomotor stress, although the scale of the study was limited.

CBG vs CBD Bioavailability – Is There a Difference?

The oral bioavailability of both cannabinoids is in the range of 6-19% (PMC, Frontiers in Pharmacology, 2020). Low bioavailability is due to the first-pass effect in the liver and the strong lipophilicity of the molecules. Differences between CBG and CBD in the same matrix, for example, MCT oil, are clinically insignificant.

The formulation is more important than the molecule itself. Nanoemulsions, MCT-based oils, liposomal capsules, and sublingual dosing can increase absorption by up to threefold. The sublingual form, i.e., drops held under the tongue for 60-90 seconds, provides 13-191 TP3T bioavailability. This is the standard offered by high-quality CBD and CBG oils.

What influences absorption? The presence of fat in a meal increases bioavailability by 3-5x in pharmacokinetic studies. Therefore, many manufacturers recommend taking the oil with a meal containing fat. MCT-based oils already contain fat in their matrix, so the effect is less dependent on the meal.

What to choose: oil, capsules, jellies?

Oils in sublingual drops are the fastest-absorbing form. The effect occurs within 15-45 minutes, with bioavailability reaching the upper end of the 13-19% range. Drops also allow for easy dose modulation, from 1 to 20 drops, depending on your needs.

Softgel capsules offer convenience and repeatable dosing. However, they are slower to act, taking 60-120 minutes, and have lower bioavailability. This is due to first-pass metabolism through the liver, where P450 enzymes metabolize a significant portion of the cannabinoids before they reach systemic circulation.

Jellies, or so-called edibles, work similarly to capsules. Additionally, they are slow-release through digestion, so the effect lasts over time. Topicals (creams, ointments) act locally and do not significantly enter the bloodstream. They are suitable for targeted muscle and joint regeneration, but not for systemic support for stress or sleep.

Nanoemulsions and other advanced formulations

Nanoemulsions are oils broken down into droplets measuring 20-200 nanometers. This form dramatically increases the surface area in contact with the mucosa and can increase bioavailability to 30-401 TP3T. Disadvantages: higher production costs and a shorter shelf life. Nanoemulsions are still rare in Poland, but the first premium products are emerging.

Cyclodextrins, liposomal forms, and hydrophilic carriers – these are the directions of development for cannabinoid formulations over the next five years. For both molecules, CBG and CBD, these technologies work similarly. There's no reason to believe that CBG requires a completely different formulation than CBD.

Citation capsule: The oral bioavailability of CBD and CBG ranges between 6% and 19%, and the sublingual form increases bioavailability to the upper end of this range (PMC, Frontiers in Pharmacology, 2020). This is why oil drops held under the tongue for 60-90 seconds are considered the gold standard for cannabinoid formulations.

Legal Status of CBG and CBD in Poland 2026

Both CBG and CBD come from Cannabis sativa L. hemp and are legal in Poland, provided that the THC content in the product does not exceed 0.3% (Journal of Laws 2005 No. 179 item 1485). None of the cannabinoids are on the list of controlled substances.

The Polish CBD market is estimated at approximately €130 million in 2024, with a growth forecast of up to €200 million in 2028 (Hemp Facts, 2024). The CBG segment is growing faster than the main CBD category. The CAGR through 2030 is 16.21 TP3T for CBG versus 12.31 TP3T for CBD (Fortune Business Insights, 2024).

An important distinction: in Poland, CBD and CBG products are sold as cosmetics or "collectibles." They are not registered as dietary supplements or medicines. This is due to the EU's status as a "novel food," which requires EFSA authorization. The process has been ongoing since 2019.

Differences in legal treatment

Legally, CBG and CBD are treated identically. The 2005 Drug Prevention Act lists only THC as a controlled substance, along with delta-9-THC and synthetic derivatives. All other natural cannabinoids from hemp are outside the scope of drug control.

Exceptions apply to synthetic products. Synthetic CBG and synthetic CBD are subject to different regulations because they are not derived from plants. In practice, 99% CBD and CBG products on the Polish market are natural extracts, so this issue only applies to pharmaceutical and research products.

What is allowed and what is not

You may: buy, possess, and use CBD and CBG products with a THC content below 0.31 TP3T. You may: sell them online and in brick-and-mortar stores. You may: carry them in carry-on luggage domestically. You may not: present them as medicines ("treats depression," "cures cancer"). You may not: sell products with THC above 0.31 TP3T.

Advertising CBD and CBG products is subject to restrictions. Health claims not approved by EFSA cannot be used. Most manufacturers use the language of "wellness support," omitting specific medical indications. This isn't a marketing ploy, but rather compliance with the law.

From the Bucha editorial office: Over the past 18 months, we've observed that customers most often ask about CBG in the context of "I can't focus at work." This is a distinctly different profile than the classic CBD query, which is "I can't sleep, I'm stressed." Therefore, in our store categorization, we've identified CBG as a separate segment, not as a subcategory of CBD.

When to choose CBD and when to choose CBG?

The choice depends on the goal, not on the "superiority" of one compound. Data from the 2023 survey shows that 66% of CBD users use it for sleep and relaxation, and 43% of CBG users use it for focus and energy (Project CBD, 2023). These are two different therapeutic "directions".

CBD is effective for chronic nervous tension, difficulty falling asleep, post-sport recovery, and joint and skin inflammation. It is an "evening" cannabinoid, with a calming effect that supports the return to homeostasis. It is most commonly used in doses of 20-50 mg daily, divided morning and evening.

CBG is more of a "morning" drug. Users report improved mental clarity, reduced muscle tension without drowsiness, and digestive support. Preclinical studies show potential for glaucoma, IBD, and neurodegenerative diseases. Doses typically range from 15-30 mg in the morning.

Scenario 1: Daily Stress and Sleep

CBD has more clinical data. 52% reduced anxiety over 8 weeks in a 2023 study (Medical Cannabis and Cannabinoids, 2023). Broad-spectrum 5-10% CBD oil, 20-40 mg daily, sublingually, morning and night, is a typical configuration. CBG acts as a support via the entourage effect but is not a key component in this scenario.

A practical tip: start with 10 mg in the evening for 3 days. Evaluate the effect on falling asleep and sleep quality. If falling asleep improves, continue with this dose. If not, increase to 20 mg. Don't jump to 50 mg immediately, as these aren't "stronger sleeping pills," and modulation of the ECS takes time.

Scenario 2: Focus and Energy

CBG works better than CBD if you're looking for "focus without drowsiness." Doses of 15-30 mg of CBG in the morning from a dedicated 10-15% oil are recommended. It doesn't combine with caffeine in an antagonistic manner. It's a synergy, not a conflict, because CBG acts on different receptors than the adenosine receptors that caffeine affects.

What does it look like in practice? Morning: coffee + 3-4 drops of CBG 15% oil. The effect is clarity of thought, reduced tension in the shoulders and neck, without the drowsiness typical of high CBD doses. This combination is recommended for those who work mentally for 8-10 hours a day.

Scenario 3: Post-Workout Recovery

The combination works best: CBD topically (ointment, balm) plus CBD orally for general inflammation, and CBG as a supplement for muscle tension. A 2021 survey showed that 39% CBG users reported a reduction in delayed-onset muscle soreness (DOMS) (Cannabis and Cannabinoid Research, 2021).

Sports protocol: Post-workout, 20-30 mg of oral CBD + CBD muscle salve. An additional 10-20 mg of CBD in the evening. The next morning, 15 mg of CBG to reduce stiffness. This regimen is used by many gym enthusiasts and long-distance runners.

Scenario 4: Inflammation and Skin

CBD topical application is effective for acne vulgaris, psoriasis, and atopic dermatitis. Studies show it works through CB2 receptors in the skin and has a direct anti-inflammatory effect on sebocytes. CBG is less well-researched in this context, but it exhibits strong antibacterial properties, which may support acne treatment.

What is the entourage effect and why does CBG enhance CBD?

The entourage effect is a phenomenon of mutual enhancement of the effects of cannabinoids and terpenes, described by Russ and Mechoulam in the British Journal of Pharmacology in 2011 (PMC, British Journal of Pharmacology, 2011). CBD and CBG work synergistically in one product. The effect is greater than the sum of the actions of the individual molecules.

The mechanism is multi-level. CBG inhibits the FAAH enzyme, responsible for the breakdown of anandamide. CBD modulates anandamide transport in cells. Together, they prolong the effects of the body's endogenous cannabinoids. Terpenes (myrcene, linalool, beta-caryophyllene) add their own synergistic effects on immune and olfactory receptors.

That's why 62% regular cannabinoid users choose broad-spectrum or full-spectrum oils that contain both cannabinoids plus terpenes (Project CBD, 2023). Isolates, i.e., pure 99% CBD or 99% CBG, have a narrower application. Mainly when dosing is accurate in studies or in the case of allergies to other cannabis components.

The difference: broad spectrum vs full spectrum

Broad spectrum is an extract containing all cannabinoids except THC. It contains CBD, CBG, CBN, CBC, and terpenes, but no THC. This is the safest form for those who don't want to risk THC detection in a drug test (professional drivers, athletes).

Full spectrum is a complete extract with all natural proportions, including trace amounts of THC up to 0.31 TP3T. Some researchers consider this form to have the strongest entourage effect. For most people, the difference is subtle, and broad spectrum is sufficient.

Isolate is 99% of pure cannabinoid. It's used in clinical trials, where it's crucial to know exactly which substance is causing the effect. In everyday use, isolates have a weaker effect per milligram than broad spectrum, precisely because of the lack of the entourage effect.

Bucha data Q1 2026: In our oil categories, the bestsellers are always broad spectrum products (approximately 78% orders), not isolates (12%) or full-spectrum with THC (10%). Polish customers prefer the "broad spectrum, but without THC" configuration, which maximizes the entourage effect without the risk of THC detection.

Synergy with terpenes

Terpenes are aromatic compounds found in cannabis and other plants. Myrcene enhances the sedative effects of CBD. Limonene has a stimulating effect and enhances mood. Beta-caryophyllene directly activates the CB2 receptor and has anti-inflammatory properties. Linalool (as in lavender) has a calming effect. Pinene improves concentration.

The terpene profile of a good quality CBD or CBG oil is declared in the certificate of analysis (COA). Check if the manufacturer publishes a COA for each batch. If not, it's likely a low-quality product. Without terpenes, we lose much of the entourage effect, even though the cannabinoids are present.

CBG and CBD Dosage – How Much to Take and How?

Typical starting doses for adults are 10-20 mg of CBD or CBG per day, increased every 3-7 days until effect is achieved (Project CBD, 2023). The WHO in a 2018 review rated CBD as well tolerated in humans at doses up to 1500 mg per day (WHO, 2018). CBG has less data, but the safety profile is similar.

The sublingual dosing guideline: one drop of standard 5% oil contains approximately 2.5 mg of cannabinoid, 10% approximately 5 mg, and 15% approximately 7.5 mg. Adjust your dose gradually. These aren't "stronger pills," but rather modulation of the ECS, which will show its full effect after 2-4 weeks of regular use.

The "start low, go slow" protocol is universal for cannabinoids. Start with the lowest dose, monitor your response for 3-7 days, and increase gradually. It's pointless to start with 100 mg daily, as this doesn't accelerate the effects and only increases the risk of side effects (primarily drowsiness and dry mouth).

When to take – morning or evening?

CBD: Flexible. Doses above 30 mg can cause mild drowsiness, so it's best taken in the evening. Lower doses (5-15 mg) can be taken in the morning without drowsiness. Many people split the dose in half, morning and evening, to maintain consistent blood levels.

CBG: Typically taken in the morning due to its "focusing" profile. Some users take CBG in the morning and CBD in the evening—a so-called "dual protocol"—to cover the entire 24-hour period. This is an advanced strategy, but it works well with most people's circadian rhythms.

The entourage effect of the broad-spectrum oil allows you to take the product at any time. One oil can be used for both morning and evening use, depending on the dose and current need. For most users, this is the most practical solution.

Can CBD and CBG be combined with medications?

Yes, but with caution. Both cannabinoids inhibit cytochrome P450 enzymes, primarily CYP3A4 and CYP2C9. This can affect the metabolism of many drugs, including warfarin, statins, antiepileptic drugs, some antidepressants (PMC, 2019). Consult your doctor or pharmacist before combining with medications.

If you are taking medications metabolized by CYP3A4 (approximately 50% medications on the market), space your doses. Take cannabinoids at least 2 hours before or after your medication. This doesn't eliminate the interaction, but it does reduce it. Monitor your effects and report any changes in your medication's effects to your doctor.

Dosage for specific conditions

Anxiety and stress: 25-50 mg of CBD daily, divided into 2-3 doses. Chronic insomnia: 40-60 mg of CBD in the evening, 1-2 hours before bed. DOMS and recovery: 20-30 mg of CBD after training, optional 15 mg of CBG in the morning. Glaucoma (in vitro studies): No approved doses for humans, CBG in preclinical phase. IBD: Preliminary data: 5-10 mg of CBG/kg body weight in mouse studies, no human data.

These are guideline doses based on literature. Everyone responds differently, so start with half the suggested dose and adjust after two weeks. If the effect is insufficient, increase by 25%. If side effects occur, reduce the dose.

The most common myths about CBG and CBD

Many myths have arisen around cannabinoids. According to a 2023 Project CBD survey, approximately 41% consumers have incorrect beliefs about the effects of CBD, while for CBG this percentage is 58% (Project CBD, 2023). It's time to sort out the facts and separate them from marketing simplifications.

Myth 1: "CBG is more potent than CBD because it is less well-known"„

False. The rarity of CBG in the plant does not translate into greater "potency." CBG activates different receptors than CBD, so it produces a different effect, but it's not a matter of "stronger vs. weaker." A 2021 survey showed that the average efficacy subjectively rated by users is comparable for both cannabinoids (Cannabis and Cannabinoid Research, 2021).

Where does this myth come from? From the marketing narrative of a "rare, valuable cannabinoid." The higher price of CBG oil stems from its lower content in the plant, not from any greater efficacy. Pharmacologically, both compounds are equally valuable in their respective areas of action.

Myth 2: "Full-spectrum oils are illegal in Poland"„

False. Full-spectrum oils are legal if the THC content does not exceed 0.31 TP3T. The difference is the trace presence of THC (0.2-0.31 TP3T) in full-spectrum, which is absent in broad-spectrum. Both are fully compliant with Polish law.

Where does the confusion arise? In some countries (e.g., the U.S. federal government), the THC limit is 0.31 TP3T, while in others (e.g., Switzerland), it's 11 TP3T. Poland has adopted a limit of 0.31 TP3T, in line with most EU countries. Imported products must meet the Polish limit, regardless of origin.

Myth 3: „CBG gets you high by binding to CB1”

False. Although CBG activates the CB1 receptor, it does so very weakly and does not produce psychoactive effects (PMC, 2020). THC has a million times stronger affinity for CB1, and this explains the difference in psychoactive effects.

Additionally, CBG acts as a weak CB1 antagonist in some research models. This means that CBG may actually reduce the effects of THC when taken together. None of the CBG users in the 2021 study reported a psychoactive high.

Myth 4: „CBD replaces depression medications”

False and potentially dangerous. CBD may support the treatment of anxiety and some mood disorders, but it is not a registered treatment for depression. Discontinuing medication without consulting a doctor can be dangerous. CBD is a complement, not a replacement.

Research suggests CBD's potential as an adjuvant to antidepressant therapy. This means "supportive supplement," not "first-line treatment." A 2020 review indicates that CBD may reduce symptoms of anxiety accompanying depression but does not treat clinical depression itself.

Myth 5: "The more CBD, the better the effect"„

False. The dose-response curve for CBD is an inverted U-shaped curve. In a 2019 study on social anxiety disorder, the 300 mg dose produced the greatest effect, with higher doses (600 mg and 900 mg) producing a weaker effect. This is typical of receptor modulators, as opposed to linear agonists.

The practical implication: don't automatically increase your dose. Find your "sweet spot" (usually 20-50 mg of CBD) and stick with it. Exceeding this dose often produces a weaker effect, not a stronger one. This is counterintuitive, but pharmacologically confirmed.

Do CBG and CBD interact with each other?

CBG and CBD work synergistically, not antagonistically. In vitro studies, a 1:1 CBG:CBD blend demonstrates stronger anti-inflammatory effects than either cannabinoid alone (PubMed, 2022). This is another argument for choosing combined oil instead of isolates.

Pharmacokinetic-wise, both cannabinoids utilize similar metabolic pathways, inhibiting the same cytochrome P450 enzymes. In practice, this means that combining CBG with CBD doesn't significantly increase the risk of drug interactions, but it doesn't reduce them either.

There is no data to suggest that CBG "displaces" CBD from receptors or vice versa. They act in parallel, on different molecular targets. This is a key difference from THC and CBD, where CBD actually modulates THC's effects through allosteric modulation of CB1.

Proportions in combined oil

Typical broad-spectrum oils have a CBD:CBG ratio of around 10:1 to 20:1, due to the plant's natural content. Some manufacturers create dedicated 1:1 CBD:CBG formulas for a "balanced" effect. Other products go the other way, such as 3:1 CBG:CBD for those seeking a CBG-dominant effect.

What's the best ratio? There's no clear answer. 10:1 CBD:CBG is the market standard and works well for most users. If you want a stronger CBG profile, choose the dedicated CBG oil 10-15% and use it alongside CBD oil.

Summary: CBG or CBD – what to choose?

CBG and CBD are two molecules with the same chemical formula but different pharmacological profiles. CBD is the "calmer sister." It activates the CB2 receptor and the 5-HT1A pathway, supporting sleep, stress, and recovery. CBG is the "focused sister." It activates CB1 and the alpha-2 adrenergic receptor, supporting concentration, muscle tone, and digestion.

The data is clear: the best effects are achieved by combining both, enhanced by the entourage effect of terpenes. Broad-spectrum oils are the optimal choice for most users. They maintain synergy without the risk of THC. Pure CBG oils make sense for those specifically testing this cannabinoid, for example, for morning concentration.

Dose gradually, starting with 10-20 mg daily and increasing every 3-7 days. Consult your doctor if you are taking medications metabolized by CYP3A4. Expect full effect after 2-4 weeks of regular use. This is not a "quiet pill," but rather modulates the endocannabinoid system.

The cannabinoid market in Poland is growing, consumer awareness is increasing, and the product selection is expanding every year. The key to success is understanding your own needs and patient testing. Cannabinoids are not a magic pill, but a proven tool for supporting wellness for many people.

Frequently asked questions

How is CBG different from CBD chemically?

CBG (cannabigerol) and CBD (cannabidiol) have the molecular formula C21H30O2, but differ in the arrangement of bonds. CBG is a biosynthetic precursor – CBD, THC, and CBC are formed from CBGA acid. In a mature cannabis plant, there is usually less than 1% of CBG compared to 10-20% of CBD (Nature, 2021).

Which cannabinoids work better for sleep – CBG or CBD?

In a 2023 clinical trial on CBD, approximately 66% participants reported improved sleep after one month of supplementation (Medical Cannabis and Cannabinoids, 2023). CBG has less clinical data, but a 2021 survey indicated improved concentration and reduced tension in 51% CBG users (Cannabis and Cannabinoid Research, 2021).

Is CBG legal in Poland in 2026?

CBG is not on the Polish list of controlled substances (Journal of Laws 2005, No. 179, item 1485, as amended). It comes from the Cannabis sativa L. hemp plant and is legal if the THC content does not exceed 0.31 TP3T. The CBG product market in Europe is growing at a CAGR of 16.21 TP3T (Fortune Business Insights, 2024).

Can you combine CBG and CBD in one oil?

Yes. Combining CBG with CBD and other cannabinoids and terpenes creates the so-called entourage effect, described in a 2011 review in the British Journal of Pharmacology (PMC, 2011). Broad-spectrum and full-spectrum oils typically contain 0.5-3% CBG alongside the main CBD fraction.

Does CBG have better bioavailability than CBD?

Both cannabinoids are highly lipophilic and have low oral bioavailability in the range of 6-19% (PMC, Frontiers in Pharmacology, 2020). MCT formulations, nanoemulsions, and sublingual dosing improve bioavailability. The differences in bioavailability between CBG and CBD are clinically insignificant when comparing the same oil matrices.

Which oils should you choose: CBG, CBD or both?

According to Project CBD data (2023), approximately 62% of regular cannabinoid users prefer combination products that utilize the entourage effect (Project CBD, 2023). If you're looking for a higher CBG fraction, choose the dedicated CBG oil 10-15%. For daily support, CBD oil 5-10%, which usually contains trace amounts of CBG, is sufficient.

Can CBG cause side effects?

A 2021 observational study included 127 CBG users. The most common side effects were dry mouth (16.5%), drowsiness (15%), and increased appetite (12%) (Cannabis and Cannabinoid Research, 2021). The safety profile is similar to CBD, but long-term clinical trials in humans are lacking.

How fast does CBG work compared to CBD?

The sublingual form typically works in 15-45 minutes, compared to 60-120 minutes for capsules and ingested products. In vitro, CBG exhibits stronger affinity for the alpha-2 adrenergic receptor than CBD (PMC, 2020), which may explain the faster perceived muscle relaxation. However, the differences in time to effect are small.

This article is for informational and educational purposes only and does not constitute medical advice. Consult your doctor before using cannabis or CBD for therapeutic purposes, especially if you are taking other medications, pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 23, 2026
Last update: April 23, 2026